Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
REGN728
Regeneron UK Limited
Healthy
1 trial -
REGN7508 (IV)
Regeneron UK Limited
Healthy Volunteer
1 trial -
REGN7544
Regeneron UK Limited
Healthy Volunteers
1 trial -
REGN7999
Regeneron UK Limited
Healthy
1 trial -
REGN846
Regeneron UK Limited
Healthy
1 trial -
REGN88
Regeneron UK Limited
Rheumatoid Arthritis
3 trials -
REGN9035
Regeneron UK Limited
Healthy Volunteers
1 trial -
REGN9533
Regeneron UK Limited
Healthy Volunteer
1 trial -
REGN9933
Regeneron UK Limited
Healthy Volunteers
1 trial -
Rilonacept
Regeneron UK Limited
Autoimmune Neurosensory Hearing Loss (ANSHL)
1 trial -
SAR231893 (REGN668)
Regeneron UK Limited
Healthy
1 trial -
SAR231893 (REGN668) DP1
Regeneron UK Limited
Healthy
1 trial -
SC-DARIC33
Regeneron UK Limited
Acute Myeloid Leukemia
1 trial -
Subconjunctival aflibercept
Regeneron UK Limited
Corneal Neovascularization
1 trial -
VEGF Trap
Regeneron UK Limited
Macular Degeneration
1 trial -
VEGF Trap
Regeneron UK Limited
Neovascular Age Related Macular Degeneration
1 trial -
VEGF Trap-Eye
Regeneron UK Limited
Diabetic Macular Edema
1 trial -
Vonsetamig
Regeneron UK Limited
Lupus Nephritis (LN)
1 trial -
aflibercept
Regeneron UK Limited
Lymphoma, Non-Hodgkin
1 trial -
aflibercept (AVE0005)
Regeneron UK Limited
Neoplasms
2 trials -
aflibercept (AVE0005)
Regeneron UK Limited
Cancer
1 trial -
autologous cell-based delivery
Regeneron Ireland Designated Activity Company (DAC)
Hypoplastic Left Heart Syndrome
1 trial -
bbT369
Regeneron UK Limited
Diffuse Large B Cell Lymphoma (DLBCL)
1 trial -
cemiplimab
Regeneron UK Limited
Relapsed/Refractory Aggressive B-Cell Lymphoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources